Filing Flows › Health Care › Korro Bio (KRRO)
Korro Bio (KRRO) earnings and revenue breakdown
Latest: Q4 2025 · 10-K filed Mar 12, 2026 · Korro Bio (KRRO) Q4 2025 earnings results →
Q4 2025 Revenue down 43% year over year to $1.3M
Korro Bio made $1.3M in Q4 2025 (-43% Y/Y). Operating margin n/m, net loss $50.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.3M in Q4 2025, down 43% year over year and up 19% from the previous quarter.
Operating costs exceeded revenue by $50.4M, an operating margin of -3900.6%. Total costs grew 104% against a revenue fall of 43%. The quarter ended with a net loss of $50.0M, wider than the previous quarter's $18.1M loss.
Operating cash flow was −$17.7M. Non-cash charges added back $649K of depreciation and $2.1M of share-based compensation. Working capital and other items added $29.6M. Capital expenditures of $84K exceeded it, leaving free cash flow of −$17.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q4 2025 | 10-K | Mar 12, 2026 | $1.3M | -43% | n/m | −$50.0M | −$17.7M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $1.1M | — | n/m | −$18.1M | −$17.2M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $1.5M | — | n/m | −$25.8M | −$19.2M |
| Q1 2025 | 10-Q | May 7, 2025 | $2.5M | — | -981.2% | −$23.4M | −$24.5M |
| Q4 2024 | 10-K | Mar 18, 2025 | $2.3M | — | n/m | −$21.2M | −$7.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Korro Bio
Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology.
In its own words, from its 8-K, filed Aug 6, 2026.
Korro Bio against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -43% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KRRO Korro Bio | Q4 2025 | $1.3M | -43% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Korro Bio 10-K on SEC EDGAR · CIK 1703647 · Pharmaceutical Preparations
13F: who owns KRRO and who is buying
More on KRRO
History
Every quarter: Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results